Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 521-529

  Murray, Onika T ^a   Wong, Chi C ^a   Vrankova, Kvetoslava ^a   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Cytoplasmic 1; Non steroidal anti inflammatory drugs; Nuclear factor of activated T cells; Pancreatic cancer; Phospho sulindac

Indexed keywords

ANIMALS; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; NFATC TRANSCRIPTION FACTORS; ORGANOPHOSPHORUS COMPOUNDS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULINDAC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893431812     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2190     Document Type: Article

References (23)

1. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004. (Pubitemid 38410779)
2. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249, 2006. (Pubitemid 43727584)
3. Bardeesy N and DePinho RA: Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909, 2002. (Pubitemid 37328891)
4. Wolfe MM, Lichtenstein DR and Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899, 1999. (Pubitemid 29272670)
5. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59: 4356-4362, 1999. (Pubitemid 29418754)
6. Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ and Schmidt CM: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther 6: 1736-1744, 2007. (Pubitemid 46954050)
7. Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA and Schmidt CM: Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther 4: 587-594, 2005. (Pubitemid 40601840)
8. Yip-Schneider MT and Schmidt CM: MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. Pancreas 7: 337-344, 2003. (Pubitemid 37337901)
9. Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, Komninou D and Rigas B: Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis 31: 1982-1990, 2010.
10. Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L and Rigas B: Phosphosulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 139: 1320-1332, 2010.
11. Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, Alston N, Zhu C, Murray OT, Constantinides PP, Kopelovich L and Rigas B: The metabolism and pharmacokinetics of phosphosulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol 165: 2152-2166, 2012.
12. Muller MR and Rao A: NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 10: 645-656, 2010.
13. Mancini M and Toker A: NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 9: 810-820, 2009.
14. Cippa PE, Kraus AK, Lindenmeyer MT, Chen J, Guimezanes A, Bardwell PD, Wekerle T, Wuthrich RP and Fehr T: Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway. Cell Death Dis 3: e299, 2012.
15. + leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 18: 74-87, 2010.
16. Sun Y and Rigas B: The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 68: 8269-8277, 2008.
17. Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, Kashfi K and Rigas B: Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res 66: 4503-4511, 2006.
18. Sun Y, Huang L, Mackenzie GG and Rigas B: Oxidative stress mediates through apoptosis the anticancer effect of phosphononsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 338: 775-783, 2011.
19. Nie T, Wong CC, Alston N, Aro P, Constantinides PP and Rigas B: Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: Anti-cancer activity in vitro and in vivo. Br J Pharmacol 166: 991-1001, 2011.
20. Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G, Gress TM and Ellenrieder V: Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 25: 3714-3724, 2006. (Pubitemid 44264881)
21. Duque J, Fresno M and Iniguez MA: Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. J Biol Chem 280: 8686-8693, 2005. (Pubitemid 40409556)
22. Cao Z and Li Y: Chemical induction of cellular antioxidants affords marked protection against oxidative injury in vascular smooth muscle cells. Biochem Biophys Res Commun 292: 50-57, 2002. (Pubitemid 34687327)
23. Hogan PG, Chen L, Nardone J and Rao A: Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17: 2205-2232, 2003. (Pubitemid 37128637)